At a 45·4-month median follow-up, HER2+ EBC patients receiving dual HER2-targeted therapy showed a reduced risk of BC recurrence or death compared with patients receiving H/chemotherapy alone, and this effect was most detectable among higher-risk patients with node-positive or HR− disease [65]. This evidence concerns the gene ERBB2 and breast cancer.